Cai Bi-He, Hsu Yun-Chien, Yeh Fang-Yu, Lin Yu-Rou, Lu Rui-Yu, Yu Si-Jie, Shaw Jei-Fu, Wu Ming-Han, Tsai Yi-Zhen, Lin Ying-Chen, Bai Zhi-Yu, Shih Yu-Chen, Hsu Yi-Chiang, Liao Ruo-Yu, Kuo Wei-Hsin, Hsu Chao-Tien, Lien Ching-Feng, Chen Chia-Chi
School of Medicine, I-Shou University, No. 8, Yida Rd., Jiaosu Village Yanchao District, Kaohsiung 82445, Taiwan.
Department of Medical Laboratory Science, I-Shou University, No. 8, Yida Rd., Jiaosu Village Yanchao District, Kaohsiung 82445, Taiwan.
Biomedicines. 2022 Jun 23;10(7):1490. doi: 10.3390/biomedicines10071490.
The members of the p53 family comprise p53, p63, and p73, and full-length isoforms of the p53 family have a tumor suppressor function. However, p53, but not p63 or p73, has a high mutation rate in cancers causing it to lose its tumor suppressor function. The top and second-most prevalent p53 mutations are missense and nonsense mutations, respectively. In this review, we discuss possible drug therapies for nonsense mutation and a missense mutation in p53. p63 and p73 activators may be able to replace mutant p53 and act as anti-cancer drugs. Herein, these p63 and p73 activators are summarized and how to improve these activator responses, particularly focusing on p53 gain-of-function mutants, is discussed.
p53家族成员包括p53、p63和p73,p53家族的全长异构体具有肿瘤抑制功能。然而,p53在癌症中的突变率很高,而p63和p73则不然,这导致p53失去其肿瘤抑制功能。最常见和第二常见的p53突变分别是错义突变和无义突变。在本综述中,我们讨论了针对p53无义突变和错义突变的可能药物治疗方法。p63和p73激活剂可能能够替代突变型p53并作为抗癌药物。在此,总结了这些p63和p73激活剂,并讨论了如何改善这些激活剂反应,特别是针对p53功能获得性突变体。